Genelux (GNLX) Other Accumulated Expenses (2024 - 2025)
Genelux's (GNLX) quarterly Other Accumulated Expenses came in at $455000.0 in Q4 2025, up 138.22% year-on-year from $191000.0 in Q4 2024, and up 138.22% quarter-over-quarter from $191000.0 in Q4 2024.
Genelux (GNLX) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Genelux's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $455000.0 for Q4 2025.
- On a quarterly basis, Other Accumulated Expenses rose 138.22% year-over-year to $455000.0 in Q4 2025; TTM through Dec 2025 was $455000.0, a 138.22% increase from a year earlier, with the FY2025 full-year figure at $455000.0, up 138.22% from the prior year.
- Other Accumulated Expenses improved to $455000.0 in Q4 2025 per GNLX's latest filing, from $191000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $455000.0 in Q4 2025 and bottomed at $191000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 455,000.00 |
| Dec 31, 2024 | 191,000.00 |